Inflammatory Neuropathy Consortium base (INCbase): a protocol of a global prospective observational cohort study for the development of a prediction model for treatment response in chronic inflammatory demyelinating polyneuropathy

期刊论文
出版模式：

开放获取
发表日期：

2024年10月25日

查看全文

Milou R. Michael,
Luuk Wieske,
Jeffrey A. Allen,
Michael P. Lunn,
Kathrin Doppler,
Cheng-Yin Tan,
Haruki Koike,
Lars K. Markvardsen,
Mahima Kapoor,
Sung-Tsang Hsieh,
Eduardo Nobile-Orazio,
Bart C. Jacobs,
Yusuf A. Rajabally,
Ivana Basta,
Paolo Ripellino,
Luis Querol,
Filip Eftimov,
Luis Querol,
Gerardo Gutiérrez-Gutiérrez,
Ivonne Jericó Pascual,
Teresa Sevilla,
German Moris,
Eugenia Martinez-Hernandez,
Arnau Llaurado-Gayete,
Marie Theaudin,
Andrea Humm,
Thomas Hundsberger,
Sara Nagy,
Agustina Lascano,
Jia-Ying Sung,
Long-Sun Ro,
Kuan-Lin Lai,
Ahmet Hoke,
Mamatha Pasnoor,
Amro M. Stino,
Karissa Gable,
Michal Vytopil,
Diana Castro

摘要

Background

INCbase is an international, multicenter prospective observational study using a customizable web-based modular registry to study the clinical, biological and electrophysiological variation and boundaries of chronic inflammatory demyelinating polyneuropathy (CIDP). The primary objective of INCbase is to develop and validate a clinical prediction model for treatment response.

Methods

All patients meeting clinical criteria for CIDP can be included in INCbase. Collected data include demographics, clinical history, diagnostics and various domains of clinical outcomes. Data is collected at a minimum of every 6 months for two years, and more frequently at the discretion of the investigational site to allow for assessment of unexpected changes in treatment response or clinical status. Participants can be enrolled in various sub-studies designed to capture data relevant to specific groups of interest. Data is entered directly into the web-based data entry system by local investigators and/or participants. Collection and local storage of biomaterial is optional. To develop a clinical prediction model for treatment response, newly diagnosed patients with active disease warranting start of first-line treatment will be included. The study population will be split into a development and validation cohort. Univariate and multivariate logistic regression analysis will be used to identify and combine predictors at start of treatment for treatment response at six months. Model performance will be assessed through discrimination and calibration in an external validation cohort. The externally validated prediction model will be made available to researchers and clinicians on the INCbase website.

Discussion

With this study, we aim to create a clinically relevant and implementable prediction model for treatment response to first line treatments in CIDP. INCbase enrollment started in April 2021, with 29 centers across 8 countries and 303 patients participating to date. This collaborative effort between academia, patient advocacy organizations and pharmaceutical industry will deepen our understanding of how to diagnose and treat CIDP.